202 related articles for article (PubMed ID: 37172100)
21. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
22. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study.
Hont AB; Cruz CR; Ulrey R; O'Brien B; Stanojevic M; Datar A; Albihani S; Saunders D; Hanajiri R; Panchapakesan K; Darko S; Banerjee P; Fortiz MF; Hoq F; Lang H; Wang Y; Hanley PJ; Dome JS; Bollard CM; Meany HJ
J Clin Oncol; 2019 Sep; 37(26):2349-2359. PubMed ID: 31356143
[TBL] [Abstract][Full Text] [Related]
24. Evolution of CD8
Sun Y; Li F; Sonnemann H; Jackson KR; Talukder AH; Katailiha AS; Lizee G
Cells; 2021 Sep; 10(9):. PubMed ID: 34572028
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
[TBL] [Abstract][Full Text] [Related]
26. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.
Ghilardi G; Chong EA; Svoboda J; Wohlfarth P; Nasta SD; Williamson S; Landsburg JD; Gerson JN; Barta SK; Pajarillo R; Myers J; Chen AI; Schachter L; Yelton R; Ballard HJ; Hodges Dwinal A; Gier S; Victoriano D; Weber E; Napier E; Garfall A; Porter DL; Jäger U; Maziarz RT; Ruella M; Schuster SJ
Ann Oncol; 2022 Sep; 33(9):916-928. PubMed ID: 35690221
[TBL] [Abstract][Full Text] [Related]
27. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
28. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Ramos CA; Grover NS; Beaven AW; Lulla PD; Wu MF; Ivanova A; Wang T; Shea TC; Rooney CM; Dittus C; Park SI; Gee AP; Eldridge PW; McKay KL; Mehta B; Cheng CJ; Buchanan FB; Grilley BJ; Morrison K; Brenner MK; Serody JS; Dotti G; Heslop HE; Savoldo B
J Clin Oncol; 2020 Nov; 38(32):3794-3804. PubMed ID: 32701411
[TBL] [Abstract][Full Text] [Related]
29. Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.
Wei T; Leisegang M; Xia M; Kiyotani K; Li N; Zeng C; Deng C; Jiang J; Harada M; Agrawal N; Li L; Qi H; Nakamura Y; Ren L
Oncoimmunology; 2021 May; 10(1):1929726. PubMed ID: 34104546
[TBL] [Abstract][Full Text] [Related]
30. T Cell Receptor Engineered Lymphocytes for Cancer Therapy.
Rollins MR; Spartz EJ; Stromnes IM
Curr Protoc Immunol; 2020 Jun; 129(1):e97. PubMed ID: 32432843
[TBL] [Abstract][Full Text] [Related]
31. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors.
Tsimberidou AM; Van Morris K; Vo HH; Eck S; Lin YF; Rivas JM; Andersson BS
J Hematol Oncol; 2021 Jun; 14(1):102. PubMed ID: 34193217
[TBL] [Abstract][Full Text] [Related]
32. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
33. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
Kim SP; Vale NR; Zacharakis N; Krishna S; Yu Z; Gasmi B; Gartner JJ; Sindiri S; Malekzadeh P; Deniger DC; Lowery FJ; Parkhurst MR; Ngo LT; Ray S; Li YF; Hill V; Florentin M; Masi RV; Paria BC; Levin N; Bera A; Hedges EA; Choi A; Chatani PD; Parikh AY; Levi S; Seitter S; Lu YC; Zheng Z; Prickett TD; Jia L; Hernandez JM; Hoang CD; Robbins PF; Goff SL; Sherry RM; Yang JC; Rosenberg SA
Cancer Immunol Res; 2022 Aug; 10(8):932-946. PubMed ID: 35749374
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Turtle CJ; Hanafi LA; Berger C; Hudecek M; Pender B; Robinson E; Hawkins R; Chaney C; Cherian S; Chen X; Soma L; Wood B; Li D; Heimfeld S; Riddell SR; Maloney DG
Sci Transl Med; 2016 Sep; 8(355):355ra116. PubMed ID: 27605551
[TBL] [Abstract][Full Text] [Related]
35. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
36. Avidity optimization of a MAGE-A1-specific TCR with somatic hypermutation.
Bassan D; Gozlan YM; Sharbi-Yunger A; Tzehoval E; Greenstein E; Bitan L; Friedman N; Eisenbach L
Eur J Immunol; 2021 Jun; 51(6):1505-1518. PubMed ID: 33835499
[TBL] [Abstract][Full Text] [Related]
37. Non-viral precision T cell receptor replacement for personalized cell therapy.
Foy SP; Jacoby K; Bota DA; Hunter T; Pan Z; Stawiski E; Ma Y; Lu W; Peng S; Wang CL; Yuen B; Dalmas O; Heeringa K; Sennino B; Conroy A; Bethune MT; Mende I; White W; Kukreja M; Gunturu S; Humphrey E; Hussaini A; An D; Litterman AJ; Quach BB; Ng AHC; Lu Y; Smith C; Campbell KM; Anaya D; Skrdlant L; Huang EY; Mendoza V; Mathur J; Dengler L; Purandare B; Moot R; Yi MC; Funke R; Sibley A; Stallings-Schmitt T; Oh DY; Chmielowski B; Abedi M; Yuan Y; Sosman JA; Lee SM; Schoenfeld AJ; Baltimore D; Heath JR; Franzusoff A; Ribas A; Rao AV; Mandl SJ
Nature; 2023 Mar; 615(7953):687-696. PubMed ID: 36356599
[TBL] [Abstract][Full Text] [Related]
38. Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells.
Yamaguchi Y; Ohta K; Kawabuchi Y; Ohshita A; Okita R; Okawaki M; Hironaka K; Matsuura K; Toge T
Anticancer Res; 2005; 25(3c):2407-15. PubMed ID: 16080467
[TBL] [Abstract][Full Text] [Related]
39. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.
Blaeschke F; Thiel U; Kirschner A; Thiede M; Rubio RA; Schirmer D; Kirchner T; Richter GHS; Mall S; Klar R; Riddell S; Busch DH; Krackhardt A; Grunewald TG; Burdach S
Oncotarget; 2016 Jul; 7(28):43267-43280. PubMed ID: 27281613
[TBL] [Abstract][Full Text] [Related]
40. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
